Status:
TERMINATED
Assessing Abuse Potential of Parenteral Buprenorphine/Naloxone in Non-Dependent Opioid Abusers
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Opioid-Related Disorders
Eligibility:
All Genders
18-55 years
Phase:
NA
Brief Summary
Buprenorphine, a treatment for opioid dependence, can be mixed with another drug, naloxone, to limit abuse potential. Parenteral administration (intravenous or intramuscular injection) of buprenorphin...
Detailed Description
Naloxone has been combined with buprenorphine to decrease the parenteral abuse potential of buprenorphine in opioid dependent individuals through the mechanism of naloxone-precipitated withdrawal. Whi...
Eligibility Criteria
Inclusion
- Non-dependent opioid abuser
- Actively abusing opioids by injection
Exclusion
- Opioid dependence
- Signs or symptoms of opioid withdrawal, once admitted to residential unit
Key Trial Info
Start Date :
December 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2017
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00134875
Start Date
December 1 2000
End Date
December 1 2017
Last Update
January 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins University (BPRU) Bayview Campus
Baltimore, Maryland, United States, 21224 6823